Navigation Links
Semafore's PI3 Kinase Inhibitor SF1126 is Active Against Tumor and Tumor Cells and Synergizes with Standard Chemotherapy Agents

SAN FRANCISCO, Oct. 26 /PRNewswire/ -- Semafore Pharmaceuticals Inc. announced today on the occasion of a poster presentation at the 2007 AACR-NCI- EORTC International Conference in San Francisco that its integrin-targeted PI3 kinase inhibitor, SF1126, showed synergistic effects with certain standard chemotherapy agents in vitro and in vivo (poster C207).

In vitro data showed significant (p<0.001) synergistic growth inhibition of prostate cancer cells with combinations of docetaxel and SF1126, as well as synergistic growth inhibition of brain cancer cells with combinations of doxorubicin and SF1126. In addition, SF1126 and rapamycin showed excellent growth inhibition synergies across all prostate, renal and non-small cell lung cancer cell lines. Simultaneous dosing of SF1126 with docetaxel in a prostate xenograft model exhibited slightly improved tumor response time versus administering SF1126 prior to docetaxel administration. In this same xenograft model, using very large tumors, it was shown that SF1126 in combination with docetaxel gave significantly greater tumor regression than did docetaxel alone (p<0.05). SF1126 as a single agent showed significant tumor growth inhibition relative to the control group (73% inhibition, p<0.01) in this model as well.

"These data support that our lead compound, SF1126, is active as a single agent and in synergy with a growing list of standard chemotherapy agents," said Edward Jacobs, Semafore's president and chief executive officer. "This provides us with a pathway to clinical development in addition to our current phase I clinical trial in patients with solid tumors. We expect to complete our phase I clinical trial in the second quarter of 2008 and then evaluate SF1126 in additional trials, both as a single and combined therapy."

About SF1126

SF1126 is a small molecule conjugate containing a pan-PI3K inhibitor that selectively inhibits all PI3K class IA isoforms and other key members of the PI3K superfamily, including DNA-PK and mTOR. A major factor in tumor resistance to approved chemotherapy agents is thought to be the activation of the PI3K/PTEN pathway. As a result, it is thought that inhibiting this pathway, via SF1126, could cause the resetting of sensitivity to approved agents and exhibit synergistic anticancer effects.

About Semafore

Semafore is a clinical stage drug discovery and development company focused on small molecule modulators of the PI3 kinase and PTEN cell signaling pathway, a promising target pathway for multiple disorders, including the company's focus--cancer. Semafore is one of the first biopharmaceutical companies to focus on both PI3K and PENN and has successfully discovered and is developing a portfolio of drug candidates addressing these targets. For more information see the company's website at

Contact: David Schull or Timothy Engel

Russo Partners, LLC


SOURCE Semafore Pharmaceuticals Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. EntreMeds Aurora Kinase Inhibitor Induces Tumor Regression in Preclinical Models
2. Data Show SuperGens Multi-Targeted Tyrosine Kinase Inhibitor Suppresses Critical Double-Stranded DNA Repair Protein, Rad51
3. Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC Inhibitor and Demonstrates Preclinical Anti-Tumor Activity with Brutons Tyrosine Kinase Inhibitors
4. AVEO Presents Preclinical Efficacy Data on AV-412, a Novel Oral Tyrosine Kinase Inhibitor of EGFR/HER2 for EGFR Mutant and Drug-Resistant Lung Cancer
5. Pharmacyclics Announces Presentations on Its Novel and Selective HDAC and Brutons Tyrosine Kinase Inhibitor Compounds
6. Sunesis Pharmaceuticals Presents SNS-314 Aurora Kinase Inhibitor Data Showing Broad Anti-Tumor Activity, Dosing Flexibility
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme
9. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
10. Anadys Pharmaceuticals Nominates ANA598, a Small-Molecule, Non-Nucleoside Inhibitor of The NS5b Polymerase, as a Candidate for Clinical Development in Chronic Hepatitis C Virus Infection
11. Ambrilia Highlights Encouraging Data for its HIV Integrase Inhibitor Program and Recent Developments at Annual Meeting
Post Your Comments:
(Date:6/23/2016)... Research and Markets has announced the addition of the ... to 2022" report to their offering. ... financial data derived from varied research sources to present unique ... on the market during the next five years, including a ... markets, regional and country level analysis. The report provides a ...
(Date:6/23/2016)... , , , WHEN: , , ... , , , LOCATION: , , , Online, with free registration ... PANELISTS:  , , , Frost & Sullivan,s Global Vice President of ... Analyst, Divyaa Ravishankar and Unmesh Lal, Program Manager , ... witnessing an exceptional era. Several new demand spaces, such as innovative ...
(Date:6/23/2016)... N.J. , June 23, 2016  Guerbet announced ... Premier Inc.,s Supplier Horizon Award . ... year, Guerbet was recognized for its support of Premier ... creation through clinical excellence, and commitment to lower costs. ... to receive this recognition of our outstanding customer service ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Those who have ... these feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, as ... Michigan, has released tools for healthy coping following a traumatic event. , Trauma sufferers ...
(Date:6/24/2016)... ... ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys are ... for this recognition are considered among the top 2 percent of lawyers practicing within ... of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. Bloom, ...
(Date:6/24/2016)... TX (PRWEB) , ... June 24, 2016 , ... People ... part in Genome magazine’s Code Talker Award, an essay contest in which patients and ... an award to be presented at the 2016 National Society of Genetic Counselors (NSGC) ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... actively feeding the Frederick area economy by obtaining investment capital for emerging technology ... past 2½ years that have already resulted in more than a million dollars ...
Breaking Medicine News(10 mins):